ArticleKidney international supplements2012
Chapter 10: Immunoglobulin A nephropathy.
Article in Kidney international supplements, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04662723 (Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.), which is not on this map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis.BMC urology · 2024Pooled it
- Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.BMC nephrology · 2017Pooled it
- Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2016Pooled it
- The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.BMC nephrology · 2022Trial
- Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.Renal failure · 2021Trial
- Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.Renal failure · 2018Trial
- Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.The Korean journal of internal medicine · 2016Trial
- Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.PloS one · 2016Trial
- A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014Trial
- IgA nephropathy management: what does the future hold?Kidney international supplements · 2026Review
- Recent Advancements in the Therapeutic Landscape of IgA Nephropathy and the Impact of Dual Blockers: Telitacicept.Kidney medicine · 2026Review
- Effect of finerenone on proteinuria reduction in IgA nephropathy.Renal failure · 2025Article
- Lupus and IgA nephropathy: coexistence or coincident?Wiener klinische Wochenschrift · 2025Review
- Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines.Pediatric nephrology (Berlin, Germany) · 2025Review
- Article
- Novel Treatment Paradigms: Primary IgA Nephropathy.Kidney international reports · 2024Review
- Article
- The Effectiveness and Safety ofEvidence-based complementary and alternative medicine : eCAM · 2022Review
- New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy.Glomerular diseases · 2022Review
- Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.